Zurich, Switzerland
NCT Number: NCT00777374
Study of Specific Allergen Immunotherapy in Grass Pollen Allergic Subjects With Epicutanoeus Allergen Administration
Seasonal rhinoconjunctivitis or hay fever is a common atopic condition that is frequently seen in clinical practice. Grass pollen is the major cause of pollinosis in many parts of the world. Immunotherapy is the only treatment that may affect the natural course of allergic diseases, and it may also prevent the development of asthma in patients with allergic rhinitis. With conventional subcutaneous desensitization the duration of treatment is around 3-5 years and usually comprises around 30-100 allergen injections. As high allergen doses have to be injected, allergic side effects may occur and patients must stay under medical supervision for at least 1 hour. Transcutaneous immunization (TCI) is a needle -free technique that delivers antigens and adjuvants to potent epicutaneous immune cells. The aim of the new epicutaneous route of desensitization is to more specifically target the immune system by loading Langerhans cells with the allergen. Lower antigen doses can be applied, such that side effects are reduced.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–65 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 2
Primary location
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Written informed consent History of grass pollen allergic rhinitis for at least two years Male and female between 18 years to 65 years Positive skin-prick test to grass pollen Positive conjunctival provocation test
Exclusion criteria
Eczematous skin lesions on the upper arms Perennial rhinitis due to perennial allergies or anatomical reason (polyps, septal deviation) Symptoms of infectious disease with rhinitis in between the last week Surgical intervention in between the last 30 days Pregnancy or nursing History of HIV or AIDS History of mastocytosis (cutaneous or systemic) History of significant cardiovascular disease Uncontrolled Hypertension (blood pressure > 160 / 95) History of significant pulmonary, renal and/or hepatic disease History of significant hematological disorder Moderate or severe asthma History of malignancy Significant neurological or psychatric disease History of active autoimmune disease Antihistamines with longed half-lives in the last week Systemic or topical steroids for 5 days Depot corticosteroids for the last two months Active infectious disease Adipositas per magna
Contraindicated medications:
- immunosuppressive agents
- Betablockers
- ACE-inhibitors, AT 2 Antagonists
- tricyclic antidepressants
- daily use of Beta-agonists or steroid inhalers
- Participation in another clinical trial /study at the moment or within the last 60 days
Treatment and study plan
Patch
Drugepicutaneous application of allergen patch
Placebo Patch
Drugepicutanoeus application of a placebo patch
Primary outcomes
-
Comparison of the efficacy of the placebo patch with the allergen patch with combined symptom medication score
Time frame: 2009 - 2011
Sponsors and collaborators
Lead sponsor
University of Zurich
Other
Registry information
Official study title
Single Center Phase I/IIa, Placebo Controlled, Randomized, Double-blind Preseasonal Study to Assess Clinical Efficacy and Safety of a Novel Method of Specific Allergen Immunotherapy in Grass Pollen Allergic Subjects by Epicutaneous Allergen Administration
Acronym: ZU-SkinSIT-003
Important dates
- Study start
- 2008
- Primary completion
- 2010
- Study completion
- 2010
- First posted
- Oct 22, 2008
- Registry last updated
- Feb 1, 2011
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction
NCT04502966
Allergic Rhinoconjunctivitis, Grass Pollen Allergy
London, United Kingdom
View Trial DetailsStudy of BLU-808 in Allergic Rhinoconjunctivitis
NCT06922448
Allergic Rhinoconjunctivitis
Ottawa, Canada
View Trial DetailsSafety and Efficacy of STALORAL® Birch 300 IR in a Paediatric Population With Birch Pollen-induced ARC w/o Asthma
NCT05668390
Allergic Rhinoconjunctivitis, Birch Pollen Allergy
Vienna, Austria
View Trial DetailsDietary Supplement (Beta-Glucans) in Allergic Patients Undergoing Subcutaneous Immunotherapy.
NCT06448585
Allergic Rhinoconjunctivitis, Controlled Asthma
Don Benito, Badajoz, Spain
View Trial Details